Ultima Genomics’ ppmSeq platform delivered early TRACERx MRD performance data at AACR, highlighting ultra-sensitive ctDNA detection at low single-digit parts per million in plasma samples. The TRACERx program, funded by Cancer Research UK, uses longitudinal and multi-region tumor sequencing across a large lung cancer cohort to track cancer evolution. In the initial validation pilot using tumor-specific variants identified from prior whole-genome sequencing, Charles Swanton of the Francis Crick Institute presented analytical sensitivity results. The company also cited collaborator data, including Labcorp’s independent analytical study reporting specificity above 99% across non-cancer donor samples, reinforcing the assay’s signal quality for MRD monitoring.